Spire Healthcare Group/£SPI
1D1W1MYTD1Y5YMAX
Capital at risk
About Spire Healthcare Group
Spire Healthcare Group PLC, listed under the ticker SPI, is a prominent provider of private healthcare in the United Kingdom. The company operates a network of private hospitals and clinics offering comprehensive treatment options spanning various medical fields. Founded in 2007, Spire Healthcare has established a reputation for clinical excellence and responsive patient care.
- Ticker
- £SPI
- Sector
- Health
- Primary listing
- LSE
- Employees
- 17,800
- Headquarters
- London, United Kingdom
- Website
- www.spirehealthcare.com
SPI Metrics
BasicAdvanced
£985M
61.50
£0.04
0.92
£0.02
0.61%
Price and volume
Market cap
£985M
Beta
0.92
52-week high
£2.57
52-week low
£1.41
Average daily volume
2.7M
Dividend rate
£0.02
Financial strength
Current ratio
0.639
Quick ratio
0.391
Long term debt to equity
1.621
Total debt to equity
1.77
Dividend payout ratio (TTM)
56.10%
Interest coverage (TTM)
1.41%
Profitability
EBITDA (TTM)
215.3
Gross margin (TTM)
45.33%
Net profit margin (TTM)
1.04%
Operating margin (TTM)
9.22%
Effective tax rate (TTM)
7.53%
Revenue per employee (TTM)
£90,000
Management effectiveness
Return on assets (TTM)
3.86%
Return on equity (TTM)
2.31%
Valuation
Price to earnings (TTM)
61.5
Price to revenue (TTM)
0.623
Price to book
1.33
Price to tangible book (TTM)
3.28
Price to free cash flow (TTM)
6.017
Free cash flow yield (TTM)
16.62%
Free cash flow per share (TTM)
0.409
Dividend yield (TTM)
0.61%
Growth
Revenue change (TTM)
4.54%
Earnings per share change (TTM)
-35.48%
3-year revenue growth (CAGR)
9.64%
10-year revenue growth (CAGR)
5.97%
3-year earnings per share growth (CAGR)
23.96%
10-year earnings per share growth (CAGR)
-12.32%
3-year dividend per share growth (CAGR)
44.23%
10-year dividend per share growth (CAGR)
-8.63%
What the Analysts think about SPI
Analyst ratings (Buy, Hold, Sell) for Spire Healthcare Group stock.
Analyst projections of the future price of Spire Healthcare Group stock.
Bulls say / Bears say
FY25 revenue reached £1.58 bn, up 4.5% y/y, driven by robust private patient demand across hospitals and clinics (Reuters)
Spire agreed to be taken over at 250 p per share by a consortium led by Toscafund, Three Hills & Ares, valuing equity at £1.03 bn and offering a near-term premium to trading levels (Reuters)
The recommended offer implies an enterprise value multiple of ~8.6x FY25 adjusted EBITDA, underscoring market willingness to pay a premium for earnings stability and growth prospects (Reuters)
Interim results for H1 ended 30 June 2026 were delayed from 9 September to 30 September, suggesting potential internal reporting or audit issues that may unsettle investors (Reuters)
Toscafund has repeatedly extended the PUSU deadline for a recommended offer, now to 3 September 2026, prolonging deal uncertainty and potential distraction for management (Reuters)
Profit before taxation fell 51.4% y/y to £18.6 m in FY25 amid elevated adjusting charges and cost inflation, demonstrating volatile earnings under current cost pressures (LSE RNS)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
SPI Financial Performance
Revenues and expenses
SPI Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SPI
AllGBPEURUSD
Fund name | Fund size | £SPI weighting |
|---|---|---|
iShares FTSE 250£MIDD | £661M | 0.21% |
Vanguard FTSE 250£VMID | £1.6B | 0.19% |
iShares Ageing Population€AGED | €822M | 0.08% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.06% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.